Markets:

Overview

News

Currencies

International

Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

4.410 +0.150 (+3.52%)

Streaming Delayed Price Updated: 11:39 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CytomX Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q3 2025 Earnings Miss, Stock Falls ↗

November 06, 2025

CytomX Therapeutics Q3 2025 earnings miss analyst estimates for revenue and EPS, triggering a negative market reaction.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 21, 2025

Via Benzinga

Why CytomX Therapeutics Stock Was Skyrocketing This Week ↗

September 26, 2025

One pundit believes the company might have a winning cancer drug in its pipeline.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 25, 2025

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

What's going on in today's after hours session ↗

September 25, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗

August 26, 2025

Via Benzinga

Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 12, 2025

Via Benzinga

CytomX (CTMX) Q2 Revenue Drops 26% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS ↗

August 07, 2025

CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism.

Via Chartmill

This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗

July 31, 2025

Via Benzinga

Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗

July 31, 2025

Via Benzinga

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via Investor Brand Network

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - A Strong Contender in High-Growth Biotech ↗

July 08, 2025

CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.

Via Chartmill

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗

May 28, 2025

Via Benzinga

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

May 20, 2025

Via Benzinga

This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday ↗

May 15, 2025

Via Benzinga

CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug ↗

May 12, 2025

The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.

Via Stocktwits

Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session. ↗

May 12, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Monday's session: most active stocks ↗

May 12, 2025

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Via Chartmill

Stocks Under $1 to Watch: TAOP, WLGS, HIT, CTMX, JYD – Major Updates, Earnings & Offerings, More Inside….

May 12, 2025

Via AB Newswire

Topics Economy

Which stocks are moving on Monday? ↗

May 12, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 12, 2025

Via Benzinga

These stocks are gapping in today's session ↗

May 12, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report ↗

May 12, 2025

CytomX reported early Phase 1 data for CX-2051 in advanced colorectal cancer, with a 94% disease control rate.

Via Benzinga

Top movers in Monday's pre-market session ↗

May 12, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.